Definitions and Guidelines for Research on Antibiotic Persistence
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Use of Ceragenins As a Potential Treatment for Urinary Tract Infections Urszula Wnorowska1, Ewelina Piktel1, Bonita Durnaś2, Krzysztof Fiedoruk3, Paul B
Wnorowska et al. BMC Infectious Diseases (2019) 19:369 https://doi.org/10.1186/s12879-019-3994-3 RESEARCH ARTICLE Open Access Use of ceragenins as a potential treatment for urinary tract infections Urszula Wnorowska1, Ewelina Piktel1, Bonita Durnaś2, Krzysztof Fiedoruk3, Paul B. Savage4 and Robert Bucki1* Abstract Background: Urinary tract infections (UTIs) are one of the most common bacterial infections. High recurrence rates and the increasing antibiotic resistance among uropathogens constitute a large social and economic problem in current public health. We assumed that combination of treatment that includes the administration ceragenins (CSAs), will reinforce the effect of antimicrobial LL-37 peptide continuously produced by urinary tract epithelial cells. Such treatment might be an innovative approach to enhance innate antibacterial activity against multidrug- resistant E. coli. Methods: Antibacterial activity measured using killing assays. Biofilm formation was assessed using crystal violet staining. Viability of bacteria and bladder epithelial cells subjected to incubation with tested agents was determined using MTT assays. We investigated the effects of chosen molecules, both alone and in combinations against four clinical strains of E. coli, obtained from patients diagnosed with recurrent UTI. Results: We observed that the LL-37 peptide, whose concentration increases at sites of urinary infection, exerts increased bactericidal effect against E. coli when combined with ceragenins CSA-13 and CSA-131. Conclusion: We suggest that the employment of combination of natural peptide LL-37 with synthetic analogs might be a potential solution to treat urinary tract infections caused by drug-resistant bacteria. Keywords: Urinary tract infection, LL-37 peptide, Ceragenins, Bacterial drug resistance Background trimethoprim/sulphamethoxazole, may no longer be used Urinary tract infections (UTIs) are one of the most com- for empiric treatment due to high resistance rates [7]. -
Zoonotic Diseases Fact Sheet
ZOONOTIC DISEASES FACT SHEET s e ion ecie s n t n p is ms n e e s tio s g s m to a a o u t Rang s p t tme to e th n s n m c a s a ra y a re ho Di P Ge Ho T S Incub F T P Brucella (B. Infected animals Skin or mucous membrane High and protracted (extended) fever. 1-15 weeks Most commonly Antibiotic melitensis, B. (swine, cattle, goats, contact with infected Infection affects bone, heart, reported U.S. combination: abortus, B. suis, B. sheep, dogs) animals, their blood, tissue, gallbladder, kidney, spleen, and laboratory-associated streptomycina, Brucellosis* Bacteria canis ) and other body fluids causes highly disseminated lesions bacterial infection in tetracycline, and and abscess man sulfonamides Salmonella (S. Domestic (dogs, cats, Direct contact as well as Mild gastroenteritiis (diarrhea) to high 6 hours to 3 Fatality rate of 5-10% Antibiotic cholera-suis, S. monkeys, rodents, indirect consumption fever, severe headache, and spleen days combination: enteriditis, S. labor-atory rodents, (eggs, food vehicles using enlargement. May lead to focal chloramphenicol, typhymurium, S. rep-tiles [especially eggs, etc.). Human to infection in any organ or tissue of the neomycin, ampicillin Salmonellosis Bacteria typhi) turtles], chickens and human transmission also body) fish) and herd animals possible (cattle, chickens, pigs) All Shigella species Captive non-human Oral-fecal route Ranges from asymptomatic carrier to Varies by Highly infective. Low Intravenous fluids primates severe bacillary dysentery with high species. 16 number of organisms and electrolytes, fevers, weakness, severe abdominal hours to 7 capable of causing Antibiotics: ampicillin, cramps, prostration, edema of the days. -
The Resistance to Host Antimicrobial Peptides in Infections Caused by Daptomycin-Resistant Staphylococcus Aureus
antibiotics Communication The Resistance to Host Antimicrobial Peptides in Infections Caused by Daptomycin-Resistant Staphylococcus aureus Md Saruar Bhuiyan 1,† , Jhih-Hang Jiang 1,† , Xenia Kostoulias 1, Ravali Theegala 1, Graham J. Lieschke 2 and Anton Y. Peleg 1,3,* 1 Infection and Immunity Program, Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, VIC 3800, Australia; [email protected] (M.S.B.); [email protected] (J.-H.J.); [email protected] (X.K.); [email protected] (R.T.) 2 Australian Regenerative Medicine Institute, Monash University, Clayton, VIC 3800, Australia; [email protected] 3 Department of Infectious Diseases, The Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC 3004, Australia * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: Daptomycin is an important antibiotic for the treatment of infections caused by Staphylococcus aureus. The emergence of daptomycin resistance in S. aureus is associated with treatment failure and persistent infections with poor clinical outcomes. Here, we investigated host innate immune responses against clinically derived, daptomycin-resistant (DAP-R) and -susceptible S. aureus paired isolates using a zebrafish infection model. We showed that the control of DAP-R S. aureus infections was attenuated in vivo due to cross-resistance to host cationic antimicrobial Citation: Bhuiyan, M.S.; Jiang, J.-H.; peptides. These data provide mechanistic understanding into persistent infections caused by DAP-R Kostoulias, X.; Theegala, R.; Lieschke, S. aureus and provide crucial insights into the adaptive evolution of this troublesome pathogen. G.J.; Peleg, A.Y. The Resistance to Host Antimicrobial Peptides in Keywords: S. -
Chapter 2 Disease and Disease Transmission
DISEASE AND DISEASE TRANSMISSION Chapter 2 Disease and disease transmission An enormous variety of organisms exist, including some which can survive and even develop in the body of people or animals. If the organism can cause infection, it is an infectious agent. In this manual infectious agents which cause infection and illness are called pathogens. Diseases caused by pathogens, or the toxins they produce, are communicable or infectious diseases (45). In this manual these will be called disease and infection. This chapter presents the transmission cycle of disease with its different elements, and categorises the different infections related to WES. 2.1 Introduction to the transmission cycle of disease To be able to persist or live on, pathogens must be able to leave an infected host, survive transmission in the environment, enter a susceptible person or animal, and develop and/or multiply in the newly infected host. The transmission of pathogens from current to future host follows a repeating cycle. This cycle can be simple, with a direct transmission from current to future host, or complex, where transmission occurs through (multiple) intermediate hosts or vectors. This cycle is called the transmission cycle of disease, or transmission cycle. The transmission cycle has different elements: The pathogen: the organism causing the infection The host: the infected person or animal ‘carrying’ the pathogen The exit: the method the pathogen uses to leave the body of the host Transmission: how the pathogen is transferred from host to susceptible person or animal, which can include developmental stages in the environment, in intermediate hosts, or in vectors 7 CONTROLLING AND PREVENTING DISEASE The environment: the environment in which transmission of the pathogen takes place. -
STD (Sexually Transmitted Disease) Or STI (Sexually Transmitted Infection): Should We Choose? Janet Byron Anderson, Phd
STD (sexually transmitted disease) or STI (sexually transmitted infection): Should we choose? Janet Byron Anderson, PhD 1. Clinical foundation of the problem Another surprise: Documented incidence had shown Each of the terms—“sexual(ly)”, “transmitted”, “disease”, that the two routes of sexual transmission were male-to- and “infection”—is problematic independently, as this female and male-to-male. However, on 15 July 2016 the study will show. Moreover, co-occurring variants, used CDC reported the first case of suspected female-to-male as synonyms in English medical articles worldwide, ag- sexual transmission in New York City [4]. Since 2008, gravate the problem. The purpose of this study is to pro- then, the Zika virus has shown that it is now sexually pose a single term that can stimulate discussion about transmissible. “Transmissible” denotes a potential, and is whether the co-occurring variants are clinically and lin- distinct from “transmitted”, which denotes a reality. guistically justifiable—especially now, when STDs/STIs To say that Zika has proved to be transmissible through have become a global health problem, and public health sexual contact means that it can be transmitted through agencies in every country are scrambling to educate their sex but that it need not be (Zika remains a chiefly vec- citizens. [Until the presentation advances to the point tor-borne disease). However, cases reported since 2008 where the question posed in the title can be definitively document the reality of transmittedness through sexual answered, I’ll use the expression “STD/STI” or the terms contact. “illness(es)” and “condition(s)”.] The predisposing epidemiologic context will first be clar- This carefully differentiated language is used by the ified, for it sheds light on two of the problematic terms: European Centre for Disease Prevention and Control chiefly “transmitted” but also “sexual(ly)”. -
Antimicrobials: Killing Persisters While They Sleep
RESEARCH HIGHLIGHTS ANTIMICROBIALS Killing persisters while they sleep Bacterial persisters are a certain metabolites can enhance of mannitol enhanced gentamicin subpopulation of dormant cells the killing of both Gram-negative killing of persister cells by more than that have been implicated in a and Gram-positive persisters by two orders of magnitude. Similarly, it may be possible range of chronic and recurrent aminoglycosides. in mice that were implanted with to eradicate infections through their ability Aminoglycoside uptake into the catheters which had been colonized bacterial to survive antibiotic treatments. bacterium is energy dependent, by a uropathogenic E. coli strain, Although most cellular processes are leading the authors to investigate administration of mannitol together persisters in a completely shut down in persisters, whether metabolic stimulation with gentamicin reduced the viability clinical setting translation still occurs, albeit at a enhances the killing of persister of biofilm bacteria on the catheter by stimulating reduced rate, making the use of cells by increasing the uptake of by more than an order of magnitude. their underlying aminoglycoside antibiotics (which these antibiotics. They found that Finally, the authors tested whether metabolic activity target the ribosome) an attractive the addition of glucose, mannitol, metabolite addition enhanced option. However, aminoglycosides fructose or pyruvate increased the aminoglycoside killing of Gram- concurrently have only weak activity against this killing of isolated Escherichia coli positive bacteria; whereas mannitol, with antibiotic subpopulation of cells. Writing persisters by gentamicin, kanamycin glucose and pyruvate had no effect, treatment. in Nature, Collins and colleagues and streptomycin by more than three the addition of fructose enhanced now show that the addition of orders of magnitude. -
Sexually Transmitted Infections Treatment Guidelines, 2021
Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 70 / No. 4 July 23, 2021 Sexually Transmitted Infections Treatment Guidelines, 2021 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS Introduction ............................................................................................................1 Methods ....................................................................................................................1 Clinical Prevention Guidance ............................................................................2 STI Detection Among Special Populations ............................................... 11 HIV Infection ......................................................................................................... 24 Diseases Characterized by Genital, Anal, or Perianal Ulcers ............... 27 Syphilis ................................................................................................................... 39 Management of Persons Who Have a History of Penicillin Allergy .. 56 Diseases Characterized by Urethritis and Cervicitis ............................... 60 Chlamydial Infections ....................................................................................... 65 Gonococcal Infections ...................................................................................... 71 Mycoplasma genitalium .................................................................................... 80 Diseases Characterized -
Transmission of SARS-Cov-2: Implications for Infection Prevention Precautions
Transmission of SARS-CoV-2: implications for infection prevention precautions Scientific brief 9 July 2020 This document is an update to the scientific brief published on 29 March 2020 entitled “Modes of transmission of virus causing COVID-19: implications for infection prevention and control (IPC) precaution recommendations” and includes new scientific evidence available on transmission of SARS-CoV-2, the virus that causes COVID-19. Overview This scientific brief provides an overview of the modes of transmission of SARS-CoV-2, what is known about when infected people transmit the virus, and the implications for infection prevention and control precautions within and outside health facilities. This scientific brief is not a systematic review. Rather, it reflects the consolidation of rapid reviews of publications in peer-reviewed journals and of non-peer-reviewed manuscripts on pre-print servers, undertaken by WHO and partners. Preprint findings should be interpreted with caution in the absence of peer review. This brief is also informed by several discussions via teleconferences with the WHO Health Emergencies Programme ad hoc Experts Advisory Panel for IPC Preparedness, Readiness and Response to COVID-19, the WHO ad hoc COVID-19 IPC Guidance Development Group (COVID-19 IPC GDG), and by review of external experts with relevant technical backgrounds. The overarching aim of the global Strategic Preparedness and Response Plan for COVID-19(1) is to control COVID-19 by suppressing transmission of the virus and preventing associated illness and death. Current evidence suggests that SARS-CoV-2, the virus that causes COVID-19, is predominantly spread from person-to-person. -
Mechanisms of Staphylococcus Aureus Persistence And
MECHANISMS OF STAPHYLOCOCCUS AUREUS PERSISTENCE AND ERADICATION OF CHRONIC STAPHYLOCOCCAL INFECTIONS by Rebecca Yee A dissertation submitted to the Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland December, 2018 ABSTRACT Bacteria can exist in different phenotypic states depending on environmental conditions. Under stressed conditions, such as antibiotic exposure, bacteria can develop into persister cells that allow them to stay dormant until the stress is removed, when they can revert back to a growing state. The interconversion of non-growing persister cells and actively growing cells is the underlying basis of relapsing and chronic persistent infections. Eradication and better treatment of chronic, persistent infections caused by Staphylococcus aureus requires a multi- faceted approach, including a deeper understanding of how the bacteria persist under stressed conditions, regulate its cell death pathways, and development of novel drug therapies. Persisters were first discovered in the 1940s in a staphylococcal culture in which penicillin failed to kill a small subpopulation of the cells. Despite the discovery many decades ago, the specific mechanisms of Staphylococcus aureus persistence is largely unknown. Recently renewed interest has emerged due to the rise of chronic infections caused by pathogens such as M. tuberculosis, B. burgdorferi, S. aureus, P. aeruginosa, and E. coli. Treatments for chronic infections are lacking and antibiotic resistance is becoming a bigger issue. The goal of our research is to define the mechanisms involved in S. aureus persistence and cell death to improve our knowledge of genes and molecular pathways that can be used as targets for drugs to eradicate chronic infections. -
Supporting North Carolina's Vaccination Efforts
Supporting North Carolina’s Vaccination Efforts Toolkit for Partner Organizations Updated June 17th, 2021 Current State of North Carolina COVID-19 Vaccinations: COVID-19 vaccines are available for free in North Carolina to everyone ages 12 and older. Those 18 and over can receive any of the three approved vaccines, while youth aged 12-17 may only receive the Pfizer vaccine. Individuals and CBOs may use the CDC Vaccine Finder to find locations that carry the Pfizer vaccine. While walk-in vaccinations are available, some locations may require appointments. In North Carolina, anyone can get vaccinated regardless of immigration status – getting vaccinated will not affect your immigration. No government-issued ID or insurance is required. Everyone can read the frequently asked questions on the DHHS website to learn more about vaccinations and what you can do after you’re vaccinated. Earning the Trust of North Carolinians: The injustices that drive the disparate impact of COVID-19 on historically marginalized populations (HMP)1 can also cause very legitimate reasons for community members to have questions about vaccines. That is why NCDHHS are working to partner with trusted leaders and organizations to provide accurate information to communities. NCDHHS is committed to earning the trust of North Carolinians related to the COVID-19 vaccine and beyond and building upon already established relationships. Organizations can consider the following strategies to support North Carolina’s vaccination efforts: 1. Share information about the COVID-19 vaccine: • Use the NCDHHS COVID-19 vaccine communications toolkit to make sure all North Carolinians have accurate and up-to-date information on the vaccine. -
Cationic Host Defense (Antimicrobial) Peptides Kelly L Brown and Robert EW Hancock
Cationic host defense (antimicrobial) peptides Kelly L Brown and Robert EW Hancock Members of the cationic host defense (antimicrobial) peptide Peptides are expressed with elements of immunity family are widely distributed in nature, existing in organisms Innate immunity is the most ancient form of immune from insects to plants to mammals and non-mammalian defense, conserved throughout the animal kingdom and vertebrates. Although many demonstrate direct antimicrobial vital to invertebrate host defenses. More recently dis- activity against bacteria, fungi, eukaryotic parasites and/or covered aspects of innate immunity — most notably, the viruses, it has been established that cationic peptides have a family of Toll-like receptors (TLRs) — have illuminated key modulatory role in the innate immune response. More the previously unrecognized complexity and heterogene- recent evidence suggests that host defense peptides are ity within the innate immune system. Many factors sup- effective adjuvants, are synergistic with other immune port important and diverse roles for antimicrobial effectors, polarize the adaptive response, and support wound peptides in immunity: the robust membership, broad healing. In addition, the mechanisms of action are being diversity in sequence and structure, thematic similarity unraveled, which support more effective implementation of of vertebrate and invertebrate antimicrobial peptides, derivatives of these endogenous peptides as therapeutic wide distribution in cells of the immune system (leuko- agents. cytes, Paneth -
Emerging Infectious Diseases
EMERGING INFECTIOUS DISEASES Javier Garau Hospital Universitari Mutua de Terrassa Universitat de Barcelona Spain Roma, 9-10 October 2008 Outline •Importance and impact of EIDs •Some definitions •Host range and EIDs and REIDs •Global trends •Getting ready for the future Leading causes of death worldwide. About 15 million (>25%) of 57 million annual deaths worldwide are the direct result of infectious disease. (http://www.who.int/whr/en) Not included the additional millions of deaths that occur as a consequence of past infections (for example, streptococcal rheumatic heart disease), or because of complications associated with chronic infections, such as liver failure and hepatocellular carcinoma in people infected with hepatitis B or C viruses. EIDS: PREPARING FOR THE FUTURE •IDs account for a quarter of all human mortality and a similar fraction of morbidity (www.who.int/whr/2005/en/) •IDs of crops and livestock cost the global economy many billions of euros every year •Sudden epidemics of IDs can deliver humanitarian and economic shocks on a scale diffricult to absorb. * United Nations, The Millenium Development goals Report 2005, New York 2005 WB Report 2003: SARS epidemic, which killed < 1000 people, was responsible for an estimated fall of 2% in GDP across East Asia •Outbreaks of livestocks (FMD, BSE, CSF, AI… ) and crop diseases (Soybean rust, Southern corn leaf blight) costing individual countries billions of euros The UN Millenium Development goals* for reducing the burden of IDs (HIV, TB, malaria), poverty and hunger (compromised by livestock and crop diseases) are gloomy: in most developing regions, where the impacts of IDs are greatest, little hope of meeting any of these goals by 2015 *United Nations, The Millenium Development goals Report 2005, New York 2005 EMERGING INFECTIONS “infections that have newly appeared in a population or have existed previously but are rapidly increasing in incidence or geographic range” Morse, S.